Mound Cotton Wollan & Greengrass partners John F. Parker and Paul S. Danner write: While the Hatch-Waxman Act has successfully brought thousands of generic drugs to the market at a much swifter rate than its branded equivalents, it has not done so without some legal pitfalls. One unanswered question has now been resolved by the Supreme Court.
'Pliva' Extended to State Claims of Design Defects in Generic Drugs
New York Law Journal
August 16, 2013